Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Costs of dyslipidemiaHanna Zowall, Steven A GroverHypertension (Dallas, Tex. : 1979)|November 17, 2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?Steven A Grover, Louis Coupal, Hanna ZowallCirculation|June 6, 2007
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF studyGordon W Moe, Jonathan Howlett, James L Januzzi, et al.Archives of Internal Medicine|February 13, 2003
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?Steven A Grover, Vivian Ho, Frédéric Lavoie, et al.The Canadian Journal of Cardiology|July 9, 2005
Cost-effectiveness of lipid-lowering treatment according to lipid levelLouise Pilote, Vivian Ho, Frédéric Lavoie, et al.The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.AIDS (London, England)|December 29, 2004
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001Eduard J Beck, Sundhiya Mandalia, Maurice Gaudreault, et al.Pageof 1